At the last check on Friday, Ensysce Biosciences Inc.’s (NASDAQ:ENSC) stock was up $0.53, moving up 16.83 percent to $3.68. The average number of shares traded per day over the past five days has been 1,709,547 shares. 5 times new highs have been achieved over the past 5 days, with a $1.08 gain in that time frame. In the last twenty days, the average volume was 1,900,292, while in the previous 50 days, it was 841,863.
Since last month, ENSC stock retreated -24.46%. Shares of the company fell to $1.90 on 11/11/22, the lowest level in the past month. A 52-week high of $140.00 was reached on 01/06/22 after having rallying from a 52-week low of $1.90. Since the beginning of this year, ENSC’s stock price has dropped by -96.65% or -$90.38, and marked a new high 2 times. However, the stock has declined by -97.37% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
ENSC stock investors should be aware that Ensysce Biosciences Inc. (ENSC) stock had its last reported insider trading activity 183 days ago on May 26. Kirkpatrick Lynn, the Chief Executive Officer of the company, purchased of 27,000 shares for $0.53 on May 26. It resulted in a $14,216 investment by the insider. Kirkpatrick Lynn added 70,000 shares at an average price of $0.49 on May 25. The insider now owns 354,851 shares following the transaction.
Right now, Ensysce Biosciences Inc. (ENSC) has a P/E ratio of about 7.02. The stock’s beta is -0.11.
In the three months ended June 29, Ensysce Biosciences Inc.’s quick ratio stood at 0.70, while its current ratio was 0.70, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.26, and the total debt-to-equity ratio was 0.26. Based on annual data, ENSC earned $23.4 million in gross profit and brought in $3.53 million in revenue.
In Ensysce Biosciences Inc.’s quarter-end financial report for June 29, it reported total debt of $1.39 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ENSC’s revenue fell -328.57% to $0.21 million during the quarter, while net income inched up to $0.28 million. While analysts expected Ensysce Biosciences Inc. to report -$0.17 quarterly earnings, the actual figure was -$0.24 per share, beating the consensus estimate by -41.20%. During the quarter, the company generated -$6.16 million in EBITDA. The liabilities of Ensysce Biosciences Inc. were 0.8 million at the end of its most recent quarter ended June 29, and its total debt was $2.67 million. The value of shareholders’ equity is $2.84 million.
This quick technical analysis looks at Ensysce Biosciences Inc.’s (ENSC) price momentum. With a historical volatility rate of 237.26%, the RSI 9-day stood at 64.60% on 23 November.
With respect to its five-day moving average, the current Ensysce Biosciences Inc. price is up by +42.52% percent or $1.08. At present, ENSC shares trade -16.93% below its 20-day simple moving average and -69.01% percent below its 100-day simple moving average. However, the stock is currently trading approximately -47.52% below its SMA50 and -89.48% below its SMA200.
Stochastic coefficient K was 75.96% and Stochastic coefficient D was 67.91%, while ATR was 0.72. Given the Stochastic reading of 61.21% for the 14-day period, the RSI (14) reading has been calculated as 55.97%. As of today, the MACD Oscillator reading stands at 0.50, while the 14-day reading stands at 0.68.
Ensysce Biosciences Inc. (ENSC) has been rated Buy by analysts. According to 0 brokerage firms, ENSC is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Ensysce Biosciences Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $8.00, the current consensus forecast for the stock is $8.00 – $8.00. Based on these forecasts, analysts predict Ensysce Biosciences Inc. (ENSC) will achieve an average price target of $8.00.